Background-MRI-detected brain lesions are common after left atrial catheter ablation for symptomatic atrial fibrillation.
L eft atrial catheter ablation (LACA) of the pulmonary veins is a well-established therapeutic approach to abolish symptomatic paroxysmal or persistent atrial fibrillation (AF) in patients who are refractory to antiarrhythmic medication. 1, 2 However, the ablation procedure generates several potential risks for thromboembolism, such as insertion of thrombogenic catheters and sheaths, left atrial endothelial lesions, systemic activation of platelets and the coagulation system, left atrial diastolic dysfunction, or air emboli via the left atrial sheaths. 3 Subsequently, LACA bears a periprocedural stroke risk of ≈0.5% and a similar risk for transient ischemic attacks. 3 MRI is likely more sensitive than clinical observation for the detection of ablation-related brain damage.
MRI studies have recently revealed that acute ischemic brain lesions occur in 4% to 41% of patients after ablation, 3, 4 a range that is dependent on the catheter device used for ablation 5, 6 and the MRI technique used for lesion detection (eg, highresolution diffusion-weighted imaging [hrDWI] ). 7 Frequently, postablation damage manifests itself in the form of silent or subclinical strokes, which do not cause overt neurological deficits but might contribute to neuropsychological impairment 8 that commonly go unnoticed. However, cognitive deficits have also been reported in patients after cardiac surgery Although catheter ablation is now a routine procedure in many centers worldwide, the present information on the clinical relevance of MRI-detected brain lesions after ablation has been generated from small case series and thus remains uncertain. 4, 12, 13 We recently reported that, in the prospective Mesh Ablator versus Cryoballoon Pulmonary Vein Ablation of Symptomatic Paroxysmal Atrial Fibrillation (MACPAF) study, 3-T hrDWI detected acute ischemic lesions in a sample of 37 LACA patients (41%) 48 hours after LACA. However, no significant cognitive decline was observed within 48 hours after ablation. 7 Here, we report the long-term follow-up data from the MACPAF study. To assess the incidence, persistence, and clinical effect of ablation-related brain lesions, which was the predefined secondary objective of the study, we performed serial brain MRI and neuropsychological testing 6 months after LACA.
We attempted to answer the following questions: (1) How many acute brain lesions postablation will form glial scars after 6 months? (2) Were these brain lesions associated with cognitive decline 6 months after ablation? (3) Does the ablation procedure itself cause neurocognitive impairment?
Methods

Study Design
The MACPAF study design has been described previously. 14, 15 Briefly, MACPAF compared the efficacy and safety of the HD Mesh Ablator catheter (C.R. Bard, Inc) and the Arctic Front catheter (Medtronic, Inc) in patients with symptomatic paroxysmal AF. MACPAF was terminated prematurely because the first interim analysis revealed an insufficient efficacy of the HD Mesh Ablator on the primary outcome measure (exit block in all pulmonary veins). 16 Overall, 37 patients underwent 41 ablation procedures according to the study criteria. Four patients with symptomatic AF episodes after ablation underwent a second LACA using the Arctic Front catheter. MRI using a 3-T device (Tim Trio; Siemens AG, Erlangen, Germany) and neurological examinations were performed within 48 hours before and after LACA and again on follow-up 6 months later. Neuropsychological assessment was scheduled before LACA, within 48 hours after ablation, and after 6 months.
MR Imaging, Neurological Examination, and Neuropsychological Examination
The MRI protocol has been described in detail previously.
7,14 MRI sequences were defined as follows: T2*-repetition time (TR), 620 ms; echo time (TE), 20 ms; field of view, 220 mm; matrix, 256×192; slice thickness, 5 mm; hrDWI-TR, 7600 ms; TE, 93 ms; field of view, 230 mm; matrix size, 192×192; slice thickness, 2.5 mm; diffusion gradients in 6 directions of b=1000 s/mm 2 , trace-weighted images, and apparent diffusion coefficient maps were post-processed; fluid-attenuated inversion recovery (FLAIR)-TR, 8000 ms; TE, 100 ms; inversion time, 2370 ms; field of view, 220 mm; matrix size, 256×232; slice thickness, 5 mm with 0.5-mm interslice gap; time-of-flight angiography-TR, 22 ms; TE, 3.86 ms; field of view, 200 mm; matrix size, 384×218; slice thickness, 0.65 mm. To ensure similar image positioning in the Figure, we used SPM8 (Wellcome Department of Imaging Neuroscience, University College London, United Kingdom) running under MATLAB (Mathworks Inc, Natick, MA). We coregistered and spatially normalized imaging data before and after ablation by using DWI B0 data as the reference category. The Wahlund score was used to quantify the extent of pre-existing white matter lesions. 17 Acute brain lesions were defined as restricted diffusion signal according to hrDWI and confirmed by coefficient mapping. The volume of the DWI lesions after ablation was calculated, and the axial diameter was categorized. Persistent brain lesions were defined as corresponding FLAIR lesions after 6 months. MRIs were interpreted by a board-certified neuroradiologist (J.B.F.).
Neurological deficits were assessed using the National Institutes of Health Stroke Scale 18 and the modified Rankin Scale. 
Ablation Procedure
Ablation procedures using the Arctic Front or the HD Mesh Ablator catheter have been described in detail previously. 16 All patients underwent transesophageal echocardiography within 24 hours before LACA to rule out cardiac thrombi. Ablation procedures were performed under sedation (using propofol and midazolam) and analgesia (using fentanyl) but without assisted ventilation. Before transseptal puncture, a heparin bolus of 2.000 IU was administered, followed by further heparin boli directly after transseptal puncture and before insertion of any ablation catheter to maintain an activated clotting time (ACT) of >300 seconds. The ACT was measured every 20 minutes, and the transseptal sheaths were flushed continuously with saline (200 mL/h) to avoid embolization. Periprocedural cardioversion was performed in cases of persisting AF after ablation of all pulmonary veins. All patients were monitored after the procedure by using a telemetric ECG system for ≥48 hours. Oral anticoagulation (vitamin K antagonists) was stopped 7 days before ablation and replaced by low-molecular-weight heparin if the international normalized ratio was <2. Anticoagulation with low-molecular-weight heparin was started on the day of LACA and followed by oral anticoagulation. Overall, 85% of all patients received oral anticoagulation for ≥6 months.
Statistical Analysis
Absolute and relative frequencies were reported for categorical variables. As a result of small sample sizes, normal distribution of continuous variables cannot be assumed. Therefore, medians and quartiles were calculated for all other variables. Fisher exact tests were used to compare proportions of dichotomous outcomes between independent groups or to test the independence of 2 dichotomous variables within a population. Mann-Whitney tests were used for group-specific location parameters, assuming equal distributions in the 2 treatment groups for ordinal outcome variables. Comparing the results of neuropsychological testing in all study patients before ablation and 6 months after ablation, we used the Wilcoxon signed-rank test. By comparing neuropsychological results in patients with or without acute/persisting brain lesions across groups, differences in individual differences of neuropsychological test results before and after ablation were computed (Tables I and II in the online-only Data Supplement for details). The resulting variables were compared using the Mann-Whitney test. Because the required sample size calculation for the MACPAF study was not met, all statistical analyses have to be regarded as exploratory. P<0.05 indicate possible associations but were not adjusted for multiple testing. Table 1 ). In other words, DWI lesions were detected after 18 (43.9%) of 41 ablation procedures. Neither age (P=0.58), sex (P=0.52), CHA 2 DS 2 VASc score (P=0.48), catheter device (P=0.11), preablation Wahlund score (P=0.34), preablation left atrial volume (P=0.18), nor periprocedural ACT levels (P=0.83) had a significant effect on the appearance of DWI lesions after ablation.
Results
Patient Characteristics and MRI Findings After Ablation
As depicted in the Figure and 
MRI Findings 6 Months After Ablation
Follow-up MRI was scheduled 6 months after LACA and performed in all patients (median, 6.5 [IQR, [6] [7] months). According to our preliminary data evaluation, 18 (48.6%) of 37 study patients had documented AF between day 90 and day 180 after ablation. None of the patients experienced territorial ischemia during follow-up. There were no acute DWI lesions after 6 months. Seven (12.5%) of the 56 DWI lesions after ablation were visible on corresponding FLAIR images in 5 (31.3%) patients. Baseline characteristics, ablationrelated factors (Table 1) , and lesion characteristics (Table 2) were compared in patients with or without persisting brain lesions. Neither age (P>0.995), sex (P>0.995), cardiovascular risk factors, medication preablation, nor ablationrelated factors such as periprocedural ACT levels, catheter device, or AF episodes during LACA had a significant effect on persistence of brain lesions. However, a corresponding FLAIR lesion immediately after ablation predicted the persistence of brain lesions (P<0.001). In addition, DWI lesion volume (P=0.06) and axial lesion diameter (P=0.07) tended to inversely associate with lesion persistence. All persistent lesions were found in patients who underwent LACA with the Arctic Front device. However, lesion volumes, diameters, and distributions did not differ according to catheter device (Table 3) .
Neuropsychological Sequelae of Periprocedural Brain Lesions
None of the patients reported neurological or cognitive deficits during follow-up. β-Blockers were discontinued in 2 patients and additively given in 2 patients within 6 months after ablation, indicating that 89% of all included patients were taking β-blockers during follow-up. Serial neuropsychological testing was complete in 35 (94.6%) of the 37 patients and after 39 (95.1%) of the 41 ablation procedures. One patient refused serial neuropsychological testing because of difficulties in understanding and speaking German and English. Another patient refused neuropsychological testing 6 months after the second ablation procedure. None of the patients complained of cognitive dysfunction on follow-up. Comparisons of interpersonal results before and after ablation (median, 6.5 [IQR, [6] [7] months) revealed that no significant changes in attention span, executive functions (assessed by the trail-making test, category and letter fluency test, and digit-span backward test), short-term memory (forward digit-span task), or verbal and nonverbal learning (Rey-Osterrieth complex figure test and the Rey auditory verbal learning test) were present (Table 4) . Reasoning performance (assessed by the LPS 50) significantly improved (P=0.002), as well as 1 domain of attention and executive functions (assessed by the color-word interference test; P=0.005). Neuropsychological differences did not differentially associate with persistent brain lesions (Table 5) . Furthermore, recurrent AF within 3 and 6 months after ablation had no effect on cognitive performance. 
Discussion
Subclinical ischemic brain lesions are frequently present in DWI acutely after LACA 7 and invasive cardiovascular procedures, such as diagnostic coronary angiography, 20, 21 patent foramen ovale occlusion, 22 percutaneous transfemoral aortic valve implantation, 23 and cardiac surgery. 24 Between 8% and 18% of all LACA patients show DWI lesions using 1.5-T imaging. 3, 4 hrDWI, however, is capable of identifying upward of twice as many (cortical) lesions as standard DWI. 12 Accordingly, we found ischemic brain lesions in 41% of all MACPAF patients who underwent hrDWI within 48 hours of LACA. These silent lesions might contribute to neuropsychological deficits and memory impairment, 8 as well as epileptic seizures, 25 but conclusive data for patients undergoing LACA are lacking.
We recently reported that no significant cognitive decline was apparent 48 hours after ablation, irrespective of the presence of acute brain lesions. 7 One case-control study, with 23 patients, found that verbal memory scores declined 3 months after LACA 26 even in patients without MRI-detected cerebral injury after ablation. Although verbal memory scores were indicative of cognitive decline, this represents only 1 dimension of neuropsychological testing. Furthermore, there was no correlation between cognitive decline and MRI-detected acute brain lesions after ablation. The authors concluded that LACA might have caused minimal ischemia or hypoxia in the hippocampus, temporal, or frontal lobe. 26 This finding has raised concerns among treating physicians and patients with AF. Yet, certain limitations of this case series do not allow substantial conclusions. 27 In contrast to Schwarz et al, 26 we observed no significant alteration in attention and executive functions, shortterm memory, or learning 6 months after LACA (Tables 4 and  5 ). Our results indicate that neither persistent brain lesions after ablation nor the ablation procedure itself had a significant effect on cognitive function after 6 months. Furthermore, recurrent AF had no effect on cognitive performance. However, deficits that affect individual skills are beyond the scope of standard test procedures. It remains to be established whether LACA can reduce AF-related cognitive decline 10, 11 by restoring sinus rhythm, as suggested by a retrospective matched-pair analysis reporting similar dementia rates across patients with AF who underwent successful LACA and patients without AF. 28 MACPAF is the first prospective trial with complete longterm follow-up MRI data. Two recent studies using 1.5-T MRI have reported that ≈6% of all brain lesions persisted (n=14 patients) after a median of 3 months 13 and that no lesions persisted (n=9 patients) after a median of 21 months. 4 Our 3-T data show that 13% of all DWI lesions 48 hours after ablation were visible as glial scars after 6 months. Lesions with smaller DWI volumes were less likely to cause glial scars, as similarly reported by Deneke et al. 13 As expected, a corresponding FLAIR lesion immediately after ablation predicted lesion persistence on FLAIR images after 6 months ( Table 2) . It is important to note that slice thicknesses on postablation hrDWI (2.5 mm) and follow-up FLAIR images (5 mm) varied and probably caused the low rate of lesion persistence. Nevertheless, DWI lesions might be fully reversible as shown in patients with transient ischemic attack without persisting brain lesion on follow-up MRI. 29 Although prevention of ablation-related complications is of clinical importance, we aimed to identify factors contributing to occurrence or persistence of ablation-related brain lesions. As similarly described for patients with acute DWI lesions immediately after ablation, 7 neither age, sex, CHA 2 DS 2 VASc score, catheter device, preablation Wahlund score, left atrial volume, nor periprocedural ACT levels associated with lesion persistence 6 months after ablation (Tables 1 and 2 ). Despite the fact that we did not observe any difference in lesion volume, size, or distribution of lesions between catheters (Table 3) , all persistent brain lesions occurred in the Arctic Front patients, likely because of the larger size of this group compared with the HD Mesh Ablator group. However, the Arctic Front ablation system has been reported to be more Values are expressed as median (IQR). DWI indicates diffusion-weighted imaging; IQR, interquartile range; LACA, left atrial catheter ablation; RAVLT, rey auditory verbal learning test; and ROC figure, Rey-Osterrieth complex figure.
*P values based on the Wilcoxon signed-rank test. †P values based on the Mann-Whitney test comparing the computed individual difference in neuropsychological test results before ablation and 6 mo after ablation across groups: the computed individual differences are available online (Table I in the online-only Data Supplement).
‡Rey auditory verbal learning test (German Version); delayed recall (A7). §Rey-Osterrieth complex figure; immediate recall. ║Subtest 3 from the German Leistungsprüfsystem (LPS).
prone to air embolism, 29 meaning that the composition of cerebral thrombi might depend on the catheter device. However, our MRI data do not enable us to verify that issue.
The prospective design of MACPAF, standardization, blinded assessment of neuropsychological testing, and the nearly complete midterm follow-up strengthen our results and address relevant clinical questions. To the best of our knowledge, MACPAF is the largest study to date that has examined possible associations between neuropsychological performance and MRI lesion persistence after LACA. The investigator-initiated MACPAF study has several limitations. First, and of major importance, because of early termination of the study, the number of study patients was limited. Therefore, we were unable to correct for multiple testing. Second, 2 patients did not undergo serial neuropsychological testing. Third, there was no control group of patients with AF not undergoing LACA. Fourth, the single-center design limits the ability to generalize our results.
Conclusions
Despite widespread use of catheter ablation for symptomatic AF, little is known about possible cognitive side effects of procedure-related brain ischemia. Serial high-sensitivity 3-T brain MRI revealed a considerably high incidence of subclinical strokes immediately after ablation, but the vast majority of these lesions had not formed a detectable glial scar on 6-month follow-up. No cognitive decline was evident in LACA patients during midterm follow-up. The same held true for patients with persisting brain lesions 6 months after the procedure. Nevertheless, prevention of procedure-related cerebral injury is vital and should be addressed in future trials using serial brain MRI.
